Categories

-

Rate of herpes infections declining

August 24, 2006

WASHINGTON, DC, United States (UPI) — A new study says the rate of genital herpes infections in the United States is declining.

The Centers for Disease Control says 17 percent of Americans had HSV-2 between 1999 and 2004, down from 21 percent between 1988 and 1994, WebMD reported.

The CDC study — published in the current issue of The Journal of the American Medical Association — is based on actual blood samples. WebMD said the report supports recent studies documenting a reduction in high-risk sex among teens.

Discount Pharmacy - Buy Pharmacy at discount prices including free shipping.Discount Pharmacy provides confortable and easy way to order discount pharmacy online.

The study also found a reduction in the rate of infection with HSV-1, the virus that causes cold sores. HSV-1, fell from 62 percent between 1988 and 1994, to 57.7 between 1999 and 2004.

The researchers warn, however, that the herpes virus that causes cold sores may one day become an important cause of genital herpes. The study says an increase in teen oral sex, which is attributed to helping reduce the rate of HSV-2, may be increasing genital infections with HSV-1.

Posted by toshko under Herpes News | Comments (0)

The Mission Ahead Against HIV and AIDS

August 20, 2006

“As the 16th international AIDS conference closes in Toronto today, we must commit ourselves to addressing the underlying causes of vulnerability to HIV,” said Helene D. Gayle, president and CEO of CARE, the international poverty-fighting organization, and co-chair of the conference. “We must change the existing social paradigm if we are going to keep pace with the virus. Otherwise, all the scientific advances in the world will not be enough. Looking to the 2008 international AIDS conference in Mexico City, we have a clear responsibility to do the hard work ahead and fulfill our responsibilities to the 40 million people living with HIV and AIDS and the millions more who risk acquiring HIV every year.”

Every year 4 million people contract HIV. It is projected that 60 million new infections will occur over the next decade. Prevention strategies already exist that could cut the number of new infections by at least 50 percent. However, less than one in five people currently at risk for HIV have access to those strategies. In addition to scaling up proven existing prevention techniques, it is critical to expand prevention options with new tools such as microbicides, diaphragms, oral preventive therapy, circumcision, herpes treatment and ultimately a vaccine. These measures are central to reducing the spread of HIV. However, neither these technologies nor anti-retroviral treatment can stop the spread of HIV and AIDS on their own. It is clear that we must go further and address the factors that increase risk to HIV, such as gender inequality and economic insecurity.

Drugs Online - Buy Drugs Online at reasanoble prices.DrugOnline.cc provides confortable and easy way to order drugs online including drugs free shipping.

This means developing more HIV programs that address underlying social factors. In Zimbabwe, for instance, CARE uses savings-based microfinance and basic business management skills to reduce the economic insecurity of vulnerable groups, including orphans, youth, widows, sex workers and people living with HIV and AIDS. This program, called SIMBA, has shown that community-managed financial systems can facilitate credit for highly vulnerable people. This access to credit (on favorable and flexible terms) can protect assets, send children to school, and pay for medical expenses. These small loans bring a certain financial stability to the household, decrease the chances that family members will be forced to migrate to find work or engage in transactional sex, which places family members at higher risk for HIV.

SIMBA has also shown that peer groups can provide a much-needed social support system for marginalized people — and help instill the self-confidence to earn a living with dignity. In addition, women who are more economically independent can better negotiate when, how and with whom they have sex. These kinds of efforts are critical to prevent the spread of HIV.

“Prevention must be at the forefront of the battle against HIV and AIDS like never before. We must offer prevention methods that are relevant to the real needs of people at risk for HIV, especially women, who are increasingly the face of HIV and AIDS. We must strive for concrete solutions to social inequities and unequal power relationships. These solutions, together with new tools, will help empower communities to make a difference in the pandemic.”

CARE fights poverty in more than 70 countries. The organization’s first HIV and AIDS program began in 1987. CARE now has more than 150 programs in approximately 40 countries that address the causes and consequences of HIV and AIDS. These programs reach over seven million people. The CARE delegation at the conference includes nearly 70 staff from Africa, Asia, Canada, Europe and the United States with expertise in HIV and AIDS.

Posted by toshko under Herpes News | Comments (0)

Anti-herpes therapy reduces genital and plasma HIV viral load in women not taking HIV therapy

August 18, 2006

Daily anti-herpes treatment significantly decreased HIV RNA in the blood and genital secretions of women not taking anti-HIV treatment, according to studies presented to the Sixteenth International AIDS Conference in Toronto on Tuesday August 15th. The investigators from France believe that their findings could have important implications for HIV prevention.

Epidemiological and biological studies have suggested a link between genital infection with herpes simplex virus-2 (HSV-2) and the transmission of HIV. HSV-2 infection may increase genital HIV shedding and possibly make co-infected individual more likely to transmit HIV to their sexual partners. However, this causal relationship has never been proven in human studies. To date, no randomised clinical trials employing anti-HSV-2 therapy have been conducted in HIV-positive individuals.

Therefore investigators from the ANRS conducted two proof-of-concept randomised, placebo-controlled trials in Burkina Faso to ascertain if the daily use of the anti-HSV-2 therapy, valaciclovir (the valine ester prodrug of aciclovir), could reduce HIV viral load in genital secretions and blood of HIV-positive women. The first study, ARNS 1285a, included HIV-positive women who did not require antiretroviral therapy; whereas the women in ARNS 1285b were taking potent HIV treatment.

In ARNS 1285a, a total of 140 women not requiring antiretroviral therapy were equally randomised to receive a daily dose of 1mg of valaciclovir or placebo for three months. Twice a week they had swabs taken from their genitals to measure genital shedding of HIV RNA and HSV-2 and blood tests to monitor their levels of HIV RNA. From the 136 women with analysable data, investigators established that the frequency and quantity of genital HIV RNA shedding and plasma HIV RNA were reduced by valaciclovir therapy by approximately 0.510 log. There was also a marked decrease in HSV-2 genital shedding by 65% as well as an 84% reduction in genital ulcers.

Discount Pharmacy - Buy Pharmacy at discount prices including free shipping.Discount Pharmacy provides confortable and easy way to order discount pharmacy online.

ANRS 1285b randomised 60 antiretroviral-taking women to valaciclovir or placebo. Median CD4 cell count in both arms was approximately 230 cells/mm3 and the median time on antiretroviral therapy was approximately 20 weeks. While there was no appreciable decrease in plasma HIV RNA, a reduction of 0.7110 log HIV RNA was seen in genital secretions. In the treatment phase, 23.7% of women had detectable genital HIV RNA compared to 8.6% receiving valaciclovir (OR=0.27; 95% CI : 0.1, 1.0; P=0.05). Thus, the women who received valaciclovir had a 73% reduction in the odds of having detectable HIV RNA in their genital secretions compared to women on placebo.

For detection of HSV-2 in genital secretions, there was a trend towards a significant difference between the groups with 6.6% of women on valaciclovir still having detectable HSV-2 compared to 9.8% of the women on placebo (P=0.06). There were also no significant differences observed in the mean quantity of genital HSV-2 DNA shedding between the groups.

The investigators proposed numerous reasons for their finding. One hypothesis was that valaciclovir treatment drives down the genital shedding of HIV by reducing plasma viral load in women who are not receiving HIV therapy. They suggest that this could be because of the impact of valaciclovir on immune mechanisms; an effect of the drug on HIV-infected cells; or, the inhibition of other herpes-related viruses. The investigators also emphasise that valaciclovir suppresses genital shedding of HSV-2, therefore reducing HIV viral load in the genitals. They caution that these data do not unequivocally demonstrate that valaciclovir is sufficient to reduce HIV-1 transmission. Wisely, they contend that this hypothesis will need to be evaluated in ongoing clinical trials, such as those being conducted by Connie Cellum and the HIV Prevention Trials Network.

They do, however, rightly point out that this is the first randomised controlled trial to demonstrate the biological impact of HSV-2 on the transmission of HIV. Likewise, they are prudent to call for further safe sex promotion to people receiving antiretrovirals after finding that up to two-thirds of the women on antiretroviral therapy still shed HIV RNA after 20 weeks.

Posted by toshko under Herpes News | Comments (0)

Updated HIV Treatment Guidelines Now Include Three GSK HIV Medications For Initial Antiretroviral Treatment Regimens

August 14, 2006

Updated treatment guidelines issued today by the International AIDS Society-USA (IAS-USA) now include three GlaxoSmithKline HIV medications as part of their recommendations for initial antiretroviral therapy. These guidelines were presented today at the International AIDS Conference (IAC) in Toronto, Canada.

In the guidelines, EPZICOM(TM) (abacavir sulfate and lamivudine) and COMBIVIR(R) (lamivudine and zidovudine) are both recommended nucleoside reverse transcriptase inhibitors, and LEXIVA(R) (fosamprenavir calcium) boosted with ritonavir is now listed among the recommended options for protease inhibitor-based regimens in the initial treatment of adults with HIV infection.

Additional information in the guidelines recommends the use of EPZICOM as an initial NRTI backbone. “Abacavir in combination with lamivudine, has comparable antiretroviral activity with the other dual NRTI components listed in the guidelines.” The guidelines also support the use of COMBIVIR as a first-line therapy based on the “extensive clinical trial data set and phase 4 experience supporting use.”

The IAS-USA commissions expert panels to issue recommendations and guidelines to provide standard approaches to patient care. The updated guidelines published in the current issue of Journal of the American Medical Association (JAMA) stated that, “[t]he choice of initial drug centers on acceptability; predicted tolerance; pill burden; comorbid conditions; short- term, mid-term and long-term adverse event profiles.”

The updated guidelines reflect the international perspectives of the panelists and are designed to serve as a tool for clinicians in countries where resources are sufficient to provide relatively unrestricted choices of drugs.

“We are pleased to see that the guidelines committee has recognized COMBIVIR, EPZICOM, and LEXIVA as important treatment options for patients with HIV,” said Mark Shaefer, Director, Clinical Development, HIV Infectious Disease Medicine Development Center at GSK.

IMPORTANT INDICATION AND SAFETY INFORMATION FOR COMBIVIR, EPZICOM, AND LEXIVA

HIV medicines do not cure HIV infection/AIDS or prevent passing HIV to others.

COMBIVIR

COMBIVIR is a combination tablet containing Epivir(R) (lamivudine, 3TC) and Retrovir(R) (zidovudine, AZT).

INDICATIO COMBIVIR is indicated in combination with other antiretroviral agents for the treatment of HIV infection.

IMPORTANT SAFETY INFORMATION

All HIV drugs have side effects. The most commonly reported side effects by patients who take COMBIVIR are: headache (35%), upset stomach (33%), fatigue (27%), and nasal signs and symptoms (20%). Patients should see their doctor regularly because serious side effects can occur, such as muscle damage and a decrease in red and white blood cells. A buildup of lactic acid in the blood and an enlarged liver, including fatal cases, have been seen.

Some patients infected with both hepatitis B virus (HBV) and HIV have worsening of hepatitis after stopping lamivudine (a component of COMBIVIR). Patients should discuss any change in treatment with your doctor. Patients who have both HBV and HIV and stop treatment with COMBIVIR should be closely monitored by a doctor for at least several months.

Worsening of liver disease (sometimes resulting in death) has occurred in patients infected with both HIV and hepatitis C virus who are taking anti-HIV medicines and are also being treated for hepatitis C with interferon with or without ribavirin. If you are taking COMBIVIR as well as interferon with or without ribavirin and you experience side effects, be sure to tell your doctor.

When you start taking HIV medicines, your immune system may get stronger and could begin to fight infections that have been hidden in your body, such as pneumonia, herpes virus, or tuberculosis. If you have new symptoms after starting your HIV medicines, be sure to tell your doctor.

Changes in body fat may occur in some patients taking antiretroviral therapy. These changes may include an increased amount of fat in the upper back and neck (”buffalo hump”), breast, and around the trunk. Loss of fat from the legs, arms, and face may also occur. The cause and long-term health effects of these conditions are not known at this time. For complete prescribing information about COMBIVIR, visit http://us.gsk.com/products/assets/us_combivir.pdf.

EPZICOM INDICATION

- EPZICOM, in combination with other antiretroviral agents, is indicated for the treatment of HIV infection in adults.

- EPZICOM is one of 3 medicines containing abacavir. Before starting EPZICOM, your healthcare professional will review your medical history in order to avoid the use of abacavir if you have experienced an allergic reaction to abacavir in the past.

- In one study, more patients had a severe hypersensitivity reaction in the abacavir once-daily group than in the abacavir twice-daily group.

- EPZICOM should not be used as part of a triple nucleoside regimen.

IMPORTANT SAFETY INFORMATION

EPZICOM contains abacavir, which is also contained in ZIAGEN(R) (abacavir sulfate) and TRIZIVIR(R) (abacavir sulfate, lamivudine, and zidovudine). Patients taking EPZICOM may have a serious allergic reaction (hypersensitivity reaction) that can cause death.

If you get a symptom from 2 or more of the following groups while taking EPZICOM, stop taking EPZICOM and call your doctor right away:

1. Fever
2. Rash
3. Nausea, vomiting, diarrhea, or abdominal (stomach area) pain
4. Generally ill feeling, extreme tiredness, or achiness
5. Shortness of breath, cough, or sore throat.

Carefully read the Warning Card that your pharmacist gives you and carry it with you at all times.

- If you stop EPZICOM because of an allergic reaction, NEVER take EPZICOM or any other abacavir-containing medicine (ZIAGEN, TRIZIVIR) again. If you take EPZICOM or any other abacavir-containing medicine again after you have had an allergic reaction, WITHIN HOURS you may get life- threatening symptoms that may include very low blood pressure or death.

- If you stop EPZICOM for any other reason, even for a few days, and you are not allergic to EPZICOM, talk with your healthcare professional before taking it again. Taking EPZICOM again can cause a serious or life-threatening reaction, even if you never had an allergic reaction before. If your healthcare professional tells you that you can take EPZICOM again, start taking it when you are around medical help or people who can call a doctor if you need one.

- A buildup of lactic acid in the blood and an enlarged liver, including fatal cases, have been reported.

- Do not take EPZICOM if your liver does not function normally.

- Some patients infected with both hepatitis B virus (HBV) and HIV have worsening of hepatitis after stopping lamivudine (a component of EPZICOM). Discuss any change in treatment with your doctor. If you have both HBV and HIV and stop treatment with EPZICOM, you should be closely monitored by your doctor for at least several months.

Drugs Online - Buy Drugs Online at reasanoble prices.DrugOnline.cc provides confortable and easy way to order drugs online including drugs free shipping.

- Worsening of liver disease (sometimes resulting in death) has occurred in patients infected with both HIV and hepatitis C virus who are taking anti-HIV medicines and are also being treated for hepatitis C with interferon with or without ribavirin. If you are taking EPZICOM as well as interferon with or without ribavirin and you experience side effects, be sure to tell your doctor.

- When you start taking HIV medicines, your immune system may get stronger and could begin to fight infections that have been hidden in your body, such as pneumonia, herpes virus, or tuberculosis. If you have new symptoms after starting your HIV medicines, be sure to tell your doctor.

- Changes in body fat may occur in some patients taking antiretroviral therapy. The cause and long-term health effects of these conditions are not known at this time.

- The most common side effects seen with the drugs in EPZICOM dosed once- daily were allergic reaction, trouble sleeping, depression, headache, tiredness, dizziness, nausea, diarrhea, rash, fever, stomach pain, abnormal dreams, and anxiety. Most of the side effects do not cause people to stop taking EPZICOM.

For full prescribing information please visit http://www.treathiv.com

LEXIVA

LEXIVA is a protease inhibitor that was co-discovered by GlaxoSmithKline and Vertex Pharmaceuticals Incorporated.

INDICATION

- LEXIVA is indicated in combination with other antiretroviral agents for the treatment of HIV infection in adults.

- The PI-experienced patient study was not large enough to reach a definitive conclusion that LEXIVA/ritonavir and lopinavir/ritonavir are clinically equivalent.

- Once-daily administration of LEXIVA/ritonavir is not recommended for PI-experienced patients. LEXIVA does not cure HIV or prevent passing HIV to others.

IMPORTANT SAFETY INFORMATION

- You should not take LEXIVA if you have had an allergic reaction to LEXIVA or AGENERASE(R) (amprenavir).

- High blood sugar, diabetes or worsening of diabetes, and bleeding in hemophiliacs have occurred in some patients taking protease inhibitors.

- When you start taking HIV medicines, your immune system may get stronger and could begin to fight infections that have been hidden in your body, such as pneumonia, herpes virus, or tuberculosis. If you have new symptoms after starting your HIV medicines, be sure to tell your doctor.

- Changes in body fat may occur in some patients taking antiretroviral therapy. The cause and long-term health effects of these conditions are not known at this time.

- Skin rashes can occur in patients taking LEXIVA. Rarely, rashes were severe or life threatening.

- Opportunistic infections can develop when you have HIV and your immune system is weak. It is very important that you see your healthcare provider regularly while you are taking LEXIVA to discuss any side effects or concerns.

- Most common side effects in clinical studies were diarrhea, headache, nausea, rash, and vomiting. In most cases, these side effects did not cause people to stop taking their medicine.

Drug Interactions

- LEXIVA should not be taken with: AGENERASE(R) (amprenavir), Halcion(R) (triazolam), ergot medications (Cafergot(R), Migranal(R), D.H.E. 45(R), and others), Propulsid(R) (cisapride), Versed(R) (midazolam), Orap(R) (pimozide), Zocor(R) (simvastatin), Mevacor(R) (lovastatin), Rifadin(R) (rifampin), Rescriptor(R) (delavirdine mesylate), or St. John’s wort (Hypericum perforatum). If you are taking Norvir(R) (ritonavir), you should not take Tambocor(R) (flecainide), or Rythmol(R) (propafenone hydrochloride).

- Serious and/or life-threatening events could occur between LEXIVA and other medications, including Cordarone(R) (amiodarone), lidocaine (intravenous only), Elavil(R) (amitriptyline HCl) and Tofranil(R) (imipramine pamoate), tricyclic antidepressants, and Quinaglute(R) (quinidine).

- Women who use birth control pills should choose a different kind of contraception. LEXIVA can affect the safety and effectiveness of birth control pills.

- Patients taking Viagra(R) (sildenafil citrate) or LEVITRA(R) (vardenafil HCl) with LEXIVA may be at an increased risk of side effects. - This list of drug interactions is not complete. Be sure to tell your healthcare provider about all medicines you are taking or plan to take, including over-the-counter drugs, vitamins, and herbals.

Resistance

- Missing or skipping doses of your medicine may make it easier for the virus to mutate and multiply. Your medicines may not work as well against a mutated virus and you may become cross-resistant to other HIV medicines. It’s important to take your medicine exactly as prescribed

Posted by toshko under Herpes News | Comments (0)

CLINICAL STUDY OF HERPES ZOSTER TREATMENT USING ACUPUNCTURE OF THUMB-JOINT ACUPOINT AND FIRE-TWINKLING METHOD

August 10, 2006

This paper is the summary of clinical results of using Acupuncture of Thumb-Joint Acupoint and Fire-Twinkling for 27 cases of Herpes Zoster, a virulent skin disease called “Yao Chan Huo Dan” and “She Du Cang” in traditional Chinese medicine. The condition usually results from decreased immune function, emotional depression, dietary disorder, malfunctional spleen and liver, or virus infection. The course of the illness lasts from two to fifteen days.

Discount Pharmacy - Buy Pharmacy at discount prices including free shipping.Discount Pharmacy provides confortable and easy way to order discount pharmacy online

The purpose of using Acupuncture of Thumb-joint Acupoint locally is to stimulate the infected region, improve the overall body immune system, and thus kill the virus using the body’s own immune functionality. Additionally, the Fire-Twinkling method utilizes the flame’s radiating and heating effect to enlarge local blood vessels, accelerate blood circulation and energize body cells. Treatment involved sterilization of Herpes Zoster with 75% alcohol, and insertion of 1-cun long #30 needles into the Herpes Zoster concentrated area at 25-degree angle, at a depth of 0.7 – 0.8 cun, with 1.5 cun apart between needles. The needles were rotated and twisted during insertion, retained for 30 to 40 minutes, and removed with the same rotating and twisting method. If blisters were clustered together they were pricked with three 3-cun needles and cleansed with medical cotton ball. For the Fire-Twinkling method, 98% alcohol was applied to a medical cotton ball and ignited. The ignited cotton ball was moved swiftly up and down toward the infected area so the flame heated the infected skin but the patient remained comfortable. Under the heat of the flame, the blisters gradually shrank in size until the skin turned dark red. In most cases, the Herpes Zoster became darker, smaller, flatter, and the patient felt less pain the next morning. One treatment was performed per day, with ten such treatments equaling one course of therapy. In most cases, two to three courses of therapy were performed. The outcome of the treatment and observation study showed that Acupuncture

Posted by toshko under Herpes News | Comments (0)

Discussing STDs with your partner is the modern relationship hurdle

August 7, 2006

“Talk to your partner about Sexually Transmitted Diseases.”

That’s the typical advice of public health agencies.

Often, though, they leave something out: How exactly does one do that?

“Hey, how ’bout them M’s? And by the way, I have herpes. How ’bout you?”

Or: “Wow, listen to the frogs out there tonight. I wonder if they have warts. Do you?”

Whether you’re contemplating your first intimate relationship, or re-entering the Wild World of Dating after a married or partnered hiatus, most people find starting that conversation roughly on par with cleaning dog poop off their shoes.

Necessary but awful. Messy if bungled. Can leave a lingering bad smell if not accomplished.

Think about the statistics: An estimated quarter of adults have genital herpes, although many haven’t recognized the symptoms. At any given time, 20 to 40 million Americans have sexually transmitted human papillomavirus (HPV) — some varieties of which can cause genital warts or cervical cancer — and most sexually active people will get it at least once, experts say.

Denial is a beautiful state of mind, but being STD-free is a beautiful state of body. And even if you have one, do you want two? Shouldn’t you be honest with someone you care about enough to have sex with?

No doubt about it, though, it’s a difficult conversation for most people — even for Brad Pitt when he approached Angelina Jolie, imagines Dennis Torres, health educator at the Madison Clinic.

Joseph, 25, a construction worker and rock climber, says he’s not offended when a woman requests he get tested before they become intimate. “They’re taking care of themselves,” he says, which helps allay his fears about her status.

At times he’s brought it up and offered to get tested. But, he admits, he’s also had sex without so much as a mention. That has led to “scares,” though, that now make him more willing to have “the talk” before sex.

Still, he tends to “beat around the bush” when he brings it up, he admits. “You could be Fabio and it’s not going to work to blurt it out,” he says. “It’ll be a turnoff.”

Scary but necessary

It might help to know that what you have to say or hear couldn’t be tougher than what 29-year-old single mom Kelly Hill has to tell a cute, interested guy: She has HIV.

She delivers the news in a straightforward way, says Hill, a peer counselor at BABES Network-YWCA, founded to build community among women facing HIV and AIDS. “It’s a matter of fact,” she says. “It needs to be known, but I don’t have a lot of drama around it.”

She’s never had a potential sexual partner react negatively, says Hill, who has been dating for the past five years. That may be because she’s educated herself about the disease, she says, and is comfortable and confident about her situation. “I’m not happy I have HIV, but it’s not all of who I am,” Hill says. “I don’t feel I did something wrong to get it, so I don’t come across as nervous or ashamed.”

Jordan, 32, who recently left military service, hasn’t had the conversation yet with the woman he’s been seeing.

But he thinks talking about their sexual histories has “great potential to deepen the intimacy of the relationship,” he says. “It’d be a lot easier to just jump into the sack, but that’s not the relationship I’m looking for.”

At the same time, he admits he’s intimidated at the prospect of talking about STDs. “It’s a scary conversation to me.”

Dr. Jeanne Marrazzo, a researcher at the University of Washington Center for AIDS and STD, isn’t surprised. The Institute of Medicine report on STDs noted: “Ironically, it may require greater intimacy to discuss sex than to engage in it.”

Not only is there fear of rejection, there’s misplaced shame about STDs and societal reluctance to talk about sex in any way, says Marrazzo. Most “traditionally trained” doctors and other providers likely won’t help get you in the groove, because “they’re really uncomfortable talking about sex.”

BABES Network-YWCA: A sisterhood of women facing HIV together: www.babesnetwork.org

The American Social Health Association: Offers information about STDs, chat rooms, newsletters and comprehensive booklets: www.ashastd.org/

More advice from “Dr. K”: (Dr. Jeffrey Klausner, director of STD Prevention and Control Services at San Francisco Department of Public Health): www.dph.sf.ca.us/sfcityclinic/drk/

Prepare yourself

OK, so you’re on your own. Where do you start?

With yourself, that’s where.

First, get screened and tested so you know your own status, says Robert Marks, disease intervention specialist supervisor for the public health STD clinic at Harborview Medical Center. “Don’t assume providers are testing you,” he says, because a lot of them “make assumptions based on appearance.”

Then, get comfortable with the facts, the lingo, with the questions this conversation may elicit. Educate yourself about treatment, protection and symptoms.

Try role-playing with a trusted friend, counselor, or even in front of a mirror, suggests Dr. Jeffrey Klausner, director of STD prevention and control for the San Francisco Department of Public Health. Play both parts, so you know how it feels to both give and get the question or information.

Drugs Online - Buy Drugs Online at reasanoble prices.DrugOnline.cc provides confortable and easy way to order drugs online including drugs free shipping.

Pay attention to your own body language, the pitch of your voice, the speed of your words. Can you speak calmly with confidence and clarity? “You are not lecturing or confessing,” says Klausner, who answers questions as “Dr. K” on the San Francisco City Clinic Web site. “You’re sharing personal information.” And remember: You’re doing it because you respect yourself and care for the other person.

Try to neutralize your “attitude” about STDs. Are you loading such a disease with all sorts of meaning that you wouldn’t attach to, say, a cold or athletes’ foot? Do you think having an STD is a sign of promiscuity, stupidity or shame?

Health educators work hard to “unload” all this baggage from STDs, Klausner notes. If you’re not ashamed about having had sex, then don’t be ashamed about STDs, he suggests. “I try to normalize it, routine-ize it, remind people that [STDs] are a common experience for anyone who is sexually active.”

Or take a page from a baby-boomer who said: “Anybody who was anybody in the ’60s has herpes.”

Try viewing the conversation as a modern ritual, a sort of expected “full disclosure” statement similar to that now demanded by medical journals from authors of research papers. Some people make testing a part of that pre-sex ritual. Marrazzo likes this opening line: “I really like you a lot, and I want this relationship to start out on a healthy footing. So let’s start out with a clean slate, and go in to get screened for STDs and other infections.”

Making the conversation and screening routine, says Marrazzo, helps “defuse blame and depersonalize responsibility for who might have brought whatever into a relationship and what your sexual past might have been.”

When and where? Not the first date, hopefully. Do it when you’re feeling relaxed and comfortable — and definitely before the clothes come off. The conversation can be the “anti-aphrodisiac,” as one doctor puts it, in the heat of the moment.

A good place is one that’s private and sexually “neutral,” such as the kitchen. Try to be on the “same ground,” both figuratively and literally, suggests Klausner, to minimize power imbalances. That means being at equal height, such as on the couch.

Here are some other openers suggested by health educators:

• “I really care about you, so there’s something I want to talk about together.”

• “I have something important to tell you.”

• Or wait until there’s a mention of STDs, or a sex scene on TV or in a movie, and go from there.

• You might say you were involved in a previous relationship and picked up an “infection.” Don’t instantly overwhelm the other person with facts, but offer to answer questions.

Be straightforward and specific, Marks suggests, not vague.

Instead of “Are you clean?” ask “What is your HIV status?”

“I encourage people to ask ‘What does that mean?’ ” Define terms, even common ones such as “monogamous” or “sex.”

If the issue is HIV, ask when a person’s last test was. “Just asking about someone’s status might not be enough,” Marks notes, because he or she may have had other encounters since then.

Expect the best of the other person if you’re disclosing your STD, Klausner says. “People usually act as you expect them to.”

But prepare for the worst. Some people will react badly to even having the conversation, much less being told their intended partner has an STD — or being asked to reveal an infection of their own.

One woman with HIV remembers a man angrily saying, “You wasted my time.” Now, she initiates the conversation as early as possible.

Hill says she would never disrespect or try to diminish a shocked reaction to her HIV disclosure. After all, that’s how she felt when the boyfriend she got it from told her.

“I do get nervous every time I tell someone,” she admits. “I’m still worried about rejection.”

“It’s never easy,” agrees Marks. “But the more you do it, the more experience you get. Let’s face it, everybody faces the issue of rejection. It’s one of the biggest barriers to bringing up the subject.”

But remember that many relationships weather bad news, Klausner suggests, and that you have survived other difficulties. “Put it in context,” he advises. “This is just another one of life’s challenges and people get over it.”

Initially, it’s a scary conversation to have, Marks says. “But once you do and you’re past it, the relief people feel can be amazing.”

Posted by toshko under Herpes News | Comments (0)

Transport Pharmaceuticals Raises $12.6M in Venture Financing

August 2, 2006

Transport Pharmaceuticals, Inc., a leader in drug/medical devices for the topical treatment of dermatological conditions, today announced that the company closed on a $12.6 million extension of its Series D financing round, bringing the total of the round to $29.6 million. This funding comes from existing investors, and was co-led by The Carlyle Group and Quaker BioVentures, with participation by The Hillman Company.

Dennis Goldberg, Ph.D., President and Chief Operating Officer, commented on the financing, “The continued support from our investors provides further validation of Transport’s technology, broad experience in drug development, management team, product focus and business strategy. The additional funds will support our lead drug/device combination product for herpes labialis, or cold sores. We will initiate a Phase II human clinical trial to evaluate the effectiveness of our new drug delivery device and proprietary acyclovir formulation. It will also help to advance the preclinical development of the Company’s onychomycosis and other product candidates.”

Richard Kollender, Partner of Quaker BioVentures added, “We continue to be attracted to Transport and its core competencies in electrical engineering, chemistry/drug formulation, materials science and drug development, a new model known as drug/device convergence. Further, Transport’s lead product focus in herpes labialis represents a unique market opportunity. This is due, in part, to the ineffectiveness of currently available treatments and the unique drug/device system developed by Transport, whereby acyclovir is delivered over a ten minute treatment time directly to impacted skin at considerably higher concentrations than existing approved topical formulations.”

Discount Pharmacy - Buy Pharmacy at discount prices including free shipping.Discount Pharmacy provides confortable and easy way to order discount pharmacy online.

About Transport’s Iontophoresis Delivery Platform

Transport’s drug/delivery platform is based on the combination of iontophoresis, a technology employing a low-voltage electrical charge to locally deliver larger amounts of medications through the skin, and proprietary drug formulations optimized for electrokinetic delivery. The Company has developed a small, wireless microprocessor-controlled drug delivery device and pre-filled drug reservoir cartridges that will allow patients to self-administer topical drugs for a variety of indications. The system consists of a reusable control unit and disposable, single-use medicated cartridges. The pre-filled cartridges contain a unit dose of drug.

About Transport’s Herpes Labialis Drug/Device

To date, Transport has clinically validated its iontophoresis technology in several US clinical trials in more than 750 patients using the company’s first generation device and an approved topical acyclovir formulation including an initial Phase IIb double-blind, placebo-controlled study in which 43 percent of treated erythema patients reported aborted lesions versus 20 percent for placebo, a 50 hour improvement in healing time for treated patients vs. placebo and a 35 hour improvement in healing time for all patients.

Posted by toshko under Herpes News | Comments (0)